INKT
Mink Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$57.60M
P/E Ratio
—
EPS
$-2.96
Beta
0.35
52W High
$76.00
52W Low
$6.34
50-Day MA
$10.89
200-Day MA
$13.12
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Mink Therapeutics Inc
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-12.46M |
| Operating Margin | 0.00% |
| Return on Equity | -1239.00% |
| Return on Assets | -79.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-3.02 |
| Price-to-Book | 10.05 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.67 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.97M |
| Float | $1.77M |
| % Insiders | 60.67% |
| % Institutions | 3.06% |
Analyst Ratings
Consensus ($39.00 target)
2
BuyData last updated: 4/8/2026